Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in Inflammatory Strictures Due to Crohn's Disease
NCT06997965Phase 4Recruiting
- Sponsor
- Alimentiv Inc.
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of mirikizumab in Crohn's disease, sponsored by Alimentiv Inc.. Started Apr 2026; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06997965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997965.